Expression of the Endothelin-axis in the different histologic subtypes of renal cell carcinoma: A tissue microarray analysis

Oncology Reports

Volumn 17, Issue 2, 2007, Pages 275-280

  Herrmann, Edwin ^a   Eltze, Elke ^a   Bierer, Stefan ^a   Bogemann, Martin ^a   Brinkmann, Olaf Anselm ^a   Balnowair, Hoda ^a   Hertle, Lothar ^a   Wulfing, Christian ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Endothelin axis; Endothelin receptors; Endothelins; Immunohistochemistry; Renal cell carcinoma; Tissue microarray

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DNA MICROARRAY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIN-1; ENDOTHELINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 33947718424     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.2.275     Document Type: Article

References (34)

1. Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31: 536-545, 2005.
2. Storkel S, Eble JN, Adlakha K, et al: Classification of renal cell carcinoma: Workgroup No. 1 Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989, 1997.
3. Higgins JP, Shinghal R, Gill H, et al: Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932, 2003. (Pubitemid 36237499)
4. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988. (Pubitemid 18090241)
5. Kusuhara M, Yamaguchi K, Nagasaki K, et al: Production of endothelin in human cancer cell lines. Cancer Res 50: 3257-3261, 1990. (Pubitemid 20190127)
6. Nelson J, Bagnato A, Battistini B and Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116, 2003. (Pubitemid 37328878)
7. Herrmann E, Bogemann M, Bierer S, Eltze E, Hertle L and Wulfing C: The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther 6: 73-81, 2006.
8. Spinella F, Rosano L, Di Castro V, Natali PG and Bagnato A: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 277: 27850-27855, 2002. (Pubitemid 34966730)
9. Wulfing C, Eltze E, Piechota H, et al: Expression of endothelin-1 and endothelin-A and -B receptors in invasive bladder cancer. Oncol Rep 13: 223-228, 2005.
10. Wulfing C, Eltze E, Yamini J, et al: Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 47: 593-600, 2005. (Pubitemid 40521902)
11. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA and Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944-949, 1995.
12. Carducci MA, Padley RJ, Breul J, et al: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679-689, 2003. (Pubitemid 46621903)
13. Jimeno A and Carducci M: Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 5: 419-427, 2005. (Pubitemid 40894976)
14. Douglas ML, Richardson MM and Nicol DL: Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 100: 2118-2124, 2004. (Pubitemid 38580329)
15. Thevarajah S, Udan MS, Zheng H and Nelson JB: Endothelin axis expression in renal cell carcinoma. J Urol 161: 137-143, 1999.
16. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD and Nelson JB: Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett (Epub ahead of print), 2006.
17. Wulfing P, Diallo R, Kersting C, et al: Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9: 4125-4131, 2003. (Pubitemid 37204029)
18. Salani D, Di Castro V, Nicotra MR, et al: Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 1537-1547, 2000.
19. Chow WH, Devesa SS, Warren JL and Fraumeni JF: Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631, 1999. (Pubitemid 29211773)
20. Motzer RJ, Bacik J and Mazumdar M: Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 10: 6302-6303, 2004.
21. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987. (Pubitemid 17041979)
22. Patel PH, Chaganti RS and Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94: 614-619, 2006. (Pubitemid 43361889)
23. Sullivan ME, Mumtaz FH, Khan MA, Dashwood MR, Thompson CS, Mikhailidis DP and Morgan RJ: Endothelins in the urinary tract. BJU Int 86: 97-106, 2000. (Pubitemid 30420773)
24. Meloni-Ehrig AM: Renal cancer: cytogenetic and molecular genetic aspects. J Med Genet 115: 164-172, 2002.
25. Ljungberg B, Alamdari FI, Stenling R and Roos G: Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 36: 565-569, 1999. (Pubitemid 29516286)
26. Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003. (Pubitemid 36514472)
27. Patard JJ, Leray E, Rioux-Leclercq N, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23: 2763-2771, 2005. (Pubitemid 46179466)
28. Grant K, Loizidou M and Taylor I: Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88: 163-166, 2003.
29. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS and Simons JW: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663-668, 1996. (Pubitemid 26059878)
30. Bagnato A, Salani D, Di Castro V, et al: Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720-727, 1999. (Pubitemid 29076073)
31. Kikuchi K, Nakagawa H, Kadono T, et al: Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 219: 734-739, 1996.
32. Lahav R, Heffner G and Patterson PH: An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 96: 11496-11500, 1999. (Pubitemid 29487409)
33. Bek EL and McMillen MA: Endothelins are angiogenic. J Cardiovasc Pharmacol 36: 135-139, 2000.
34. Nelson, JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW and Inoue N: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063-1069, 1999. (Pubitemid 29196330)